Poster zum Thema "Chronic Infections"

Zurück
  • P-1-100
Predictors of postviral symptoms following Epstein-Barr-Virus-Associated infectious Mononucleosis in young people – data from the IMMUC Study
  • P-1-101
Longitudinal metabolomic profiling in long COVID
  • P-1-102
Targeting immune checkpoint receptor ligands to restore T cell activity and eliminate persisting hepatitis B virus infection
  • P-1-103
Investigation of the HBV infection cycle of rabbit hepatocytes
  • P-1-104
TIGIT-expression on NK cell subsets is an early indicator of alleviating liver inflammation following BLV treatment in chronic hepatitis D
  • P-1-105
Purification of HBV core antigen particles using a one-step anion exchange chromatography process
  • P-1-106
Spectrum and prevalence of psychiatric disorders depending on latent toxoplasmosis at initial HIV diagnosis in 2019 and 2020 – HIV/PSYCH
  • P-1-107
Bulevirtide in combination with pegylated interferon alfa-2a shows a sustained response to treatment in the liver
  • P-1-108
Assessing determinants of optimal replication fitness for a subgenomic replicon vaccine against hepatitis C virus
  • P-1-109
Cytotoxic CD16+ γδ T cells ere associated with virus control in chronic Hepatitis B virus (HBV) infection by mediating antibody-dependent cellular cytotoxicity (ADCC)
  • P-1-110
Intactness and function of Nef proteins from an elite-neutralizer patient cohort
  • P-1-111
Persistent changes in the NK cell and UTC immune signatures after cure of hepatitis C
  • P-1-112
Improved targeting of human CD4+ T cells by single domain antibody coupled lipid nanoparticles
  • P-1-113
Inflammation metabolism in tuberculosis: Impact of ROS and RedOx Metabolites on active TB pathology and PTLD development
  • P-1-114
Early Neutrophil associated markers correlating with postTB lung impairment in MDR TB
  • P-1-115
Dissecting host immune responses in hepatitis E virus infection: NanoString analysis across diverse disease courses
  • P-1-116
Analysis of the CXCL9-11/CXCR3 axis in hepatitis D
  • P-1-117
Targeting the methyl-D-erythritol phosphate (MEP) pathway in M. tuberculosis: CRISPRi-based hypomorphs and novel reporter strains in antitubercular compound discovery
  • P-1-118
Ten-year follow-up after 96 weeks treatment with peginterferon plus tenofovir in hepatitis D (HIDIT-II)
  • P-1-119
Post covid predictors in the cross-sectional cohort platform (SUEP) of the national pandemic cohort network (NAPKON) in Germany
  • P-1-120
Genome-wide transcriptome analysis reveals unique transcriptional control of effector functions in tissue-resident CD8 T cells during persistent viral infection
  • P-1-121
Anti-HDV prevalence and virological characteristics of samples in routine diagnostics at a major German university hospital (2008–2024)
  • P-1-122
Pediatric tuberculosis testing: A systematic review and meta-analysis of individual participant data comparing the diagnostic yield of urine and respiratory tests for pulmonary tuberculosis in children
  • P-1-94
HIF-2α Pathway Inhibition as a therapeutic strategy for Endothelial Dysfunction and Hypoxia in Long COVID
  • P-1-95
Characterization of COX6C as a proviral factor in HBV infection and its role in oxidative phosphorylation
  • P-1-96
Improving T cell control of HCMV with a mAb targeting the immunosuppressive glycoprotein pUL11
  • P-1-97
High-risk human papillomavirus persistence and incidence among women living with HIV in the African Cohort Study
  • P-1-98
Dissecting the impact of HIV on HPV-specific immunity, viral persistence and molecular signatures of cervical dysplasia
  • P-1-99
Human intestinal organoids to study the stem cell niche as a potential reservoir for hepatitis E virus infections